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Guidelines for the diagnosis and treatment of a given disease
are intended to ensure high-quality medical care. The
German Neurological Society’s (Deutsche Gesellschaft für
Neurologie, DGN) Guideline on Diagnosis and Treatment of
Multiple Sclerosis, Neuromyelitis Optica Spectrum Diseases
and MOG-IgG-Associated Disorders [1] has recently been
revised and published in German. This consensus-based
guideline (S2k level according to the classification of the
Association of the Scientific Medical Societies in Germany
[Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen
Fachgesellschaften e.V., AWMF]) aims to provide answers to
questions of daily practice, including areas where evidence is
sparse, without limiting physicians’ freedom of decision. A
clear focus was set on safeguarding patient autonomy; to
this end, patient representatives were involved throughout
the entire guideline development process.
Key question 1. When should patients receive a
disease-modifying treatment?
Before or after the onset of disease progression? Or even after
a clinically isolated syndrome (e.g. isolated optic neuritis)?
The selection and timing of disease-modifying drugs
(DMDs) in clinically isolated syndromes (CIS) not fulfilling
the 2017 diagnostic MS criteria and in multiple sclerosis
(MS) is one of the central issues addressed in the DGN
guideline [1]. In MS, the prevention of disability accrual is
the central goal of all immunomodulatory treatments and
there is no doubt that this should start early and according
to need.
In the DGN guideline, CIS is defined as a first mani-
festation (relapse), with the criterion of dissemination in
space being fulfilled, but not dissemination in time. The
lack of reliable predictive markers for the individual
disease course and response to DMDs makes treatment
decisions challenging. According to the DGN guideline,
the purpose of DMD treatment is to reduce relapse
frequency, slow the progression of disability, and decrease
disease activity as detected by magnetic resonance imaging
(MRI) (see Appendix, statement A14).
In patients who experience a first relapse without
fulfilling the criteria of dissemination in time and space
(e.g. isolated optic neuritis or myelitis) and therefore
cannot be diagnosed with MS or CIS on the basis of the
2017 criteria, DMDs should be used only exceptionally
(see A20), since there are no controlled studies on
DMDs in this patient group.
A central and strong recommendation in the DGN
guideline is to start DMDs in patients diagnosed with
CIS or relapsing–remitting MS (RRMS) (see A16), based
on the known positive effects of early treatment on the
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long-term disease course [2]. Permanent disability can
and must be avoided by the timely use of DMDs.
This recommendation is in line with the ECTRIMS/
EAN guidelines, which recommend that DMDs be
offered to patients who have CIS and abnormal findings
on MRI, with lesions suggestive of but not fulfilling the
criteria for MS, and propose early treatment with DMDs
in patients with active RRMS, as defined by clinical re-
lapses and/or MRI activity [3].
Additionally, statement A24 strongly recommends that
DMDs be offered to patients with clinical or MRI activ-
ity within the previous approximately 2 years.
Beyond the ECTRIMS/EAN guidelines, however, the
DGN guideline aims to provide more specific guidance
on DMD selection in particular situations, e.g. to offer
treatment-naive patients higher-efficacy drugs from the
start in the presence of evidence for a probably highly
active disease course (as outlined in key question 2).
Notably, observational studies [4, 5] have, in some
patients, described a mild MS long-term disease course
despite the absence of any reliably predictive markers for
individual prognosis at disease onset. Taking this into
account, the DGN guideline states that one may consider
(weak recommendation), refraining from DMD initi-
ation, given that the benefits and risks of starting treat-
ment have been thoroughly discussed with the patient,
and provided that the patient is monitored closely. The
prerequisite for this consideration, according to the
guideline, is the assumption of a mild disease course
based on patients’ characteristics at the time of disease
onset and/or, if available, the subsequent disease course.
The relevant characteristics include the severity of and
recovery from the first relapse, relapse frequency, MRI
lesion load and activity, and cerebrospinal fluid parame-
ters, which should be assessed (see A16). Notwithstand-
ing, the panel feels that several patient characteristics
constitute unequivocal reasons for initiation of treatment
after the first relapse: young age, polysymptomatic re-
lapse and incomplete recovery from relapse, high lesion
load and/or spinal or infratentorial lesions on MRI, and
intrathecal synthesis of immunoglobulin G or M.
Given the fact that intrathecal immunoglobulin G or
M synthesis is frequent in MS (58.2% for IgG and 21.7%
for IgM in a recent study [6] on CIS and MS, based on
the 2015 revised McDonald criteria), the option not to
initiate a DMD is clearly an exception, applicable only to
a small proportion of patients. This number drops
further when the other prognostic factors mentioned
above are reviewed in individual patients.
Overall, the DGN guideline clearly recommends
DMDs for the treatment of patients with MS and CIS.
In selected cases, however – in clinical practice, probably
few in number – the option not to start DMD treatment
first may be considered, provided that the individual
patient’s characteristics are indicative of a very favourable
disease course and that they are monitored closely. This
option was explicitly supported by the patient representa-
tives involved in the panel.
Key question 2. When should patients receive
which disease-modifying treatment?
Always drugs with limited efficacy but established long-
term safety first? Or higher-efficacy drugs for a fraction of
patients from the beginning? Individual choice or rigid
escalation of treatment?
With more than a dozen DMDs now available, categor-
isation of these drugs is necessary to facilitate treatment
decisions. The panel felt that dichotomisation into base-
line vs escalation DMDs is oversimplified, particularly
because drugs in the latter category vary widely in effi-
cacy. Seeking a suitable criterion, the panel decided to
use the drug-related reduction in relapse rate, available
from the pivotal clinical trials. Although the panel fully
realises that, owing to differences in baseline characteris-
tics and study design, this measure cannot be compared
across studies with full scientific diligence, it represents,
in the absence of head-to-head clinical trials for most
DMDs, an acceptable approximation. Following this
concept, the panel agreed to classify the available DMDs
for relapsing MS (RMS) - based on the relative reduction
of relapse rate, MRI activity and relapse-related pro-
gression (see A17) - into three categories of efficacy
(see A18):
 Efficacy category 1: beta-interferons, dimethyl
fumarate, glatirameroids, teriflunomide
 Efficacy category 2: cladribine, fingolimod, ozanimod
 Efficacy category 3: alemtuzumab, anti-CD20
antibodies (ocrelizumab, rituximab), natalizumab
These categories are intended to provide orientation
when choosing the appropriate drug for a given disease
activity; they do not dictate a “therapeutic ladder”.
Instead, immunotherapy for RMS should be selected
individually based on the activity of the disease, consid-
ering relapse frequency, relapse severity, response to
relapse therapy, disease progression and MRI findings
(see A23 and Fig. 1).
But what is “probably highly active”? Unfortunately, to
date, there is no unequivocal definition of what consti-
tutes a highly active disease, at least not one derived
from controlled prospective clinical data. Striving to fill
this gap, the panel members suggested criteria based on
the findings of the 2018 ECTRIMS Focused Workshop
Group on aggressive MS [7] (see A28):
DMD-naive RMS patients meeting one or more of the
following clinical criteria are considered as suffering
from probably highly active MS:
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 A relapse has led to clinical deficit affecting activities
of daily life despite relapse therapy
 Recovery is insufficient following the first two relapses
 The relapse rate is high, i.e. ≥ 3 in the (approx.)
first 2 years or ≥ 2 in the (approx.) first year since
disease onset
 EDSS ≥3 in the (approx.) first year since disease onset
 Pyramidal signs in the (approx.) first year since
disease onset
The panel agreed that MRI criteria only, without a
clinical criterion, are insufficient to assume a probably
highly active disease course in DMD-naive patients. In
the presence of such a criterion, however, the MRI
findings (high T2 lesion load, more than one contrast-
enhancing lesion, infratentorial/spinal lesions) were
considered of high relevance for selecting the first DMD
in treatment-naive patients.
In addition, MRI criteria were included in the working
definition of an active disease despite DMD treatment.
In patients with RMS on DMD for more than 6months
the disease is defined as active when one or more of the
following conditions is fulfilled within the preceding 2
years (see A32):
 Confirmation of a relapse (e.g. by objective clinical
findings)
 A relapse and one or more new MS-specific MRI lesion
 At two or more time points, one or more new
MS-specific MRI lesions.
This definition is again linked to the strong recommen-
dation (see A33) that patients who have an active disease
course on treatment with DMD of efficacy category 1 be
switched to DMD of efficacy category 2 or even 3, depend-
ing on the extent of the inflammatory activity.
Thus, the DGN guideline advocates an individual
choice of DMD to treat each patient as needed. This
may include timely DMD escalation, but DMD titra-
tion is by no means mandatory. But why not treat
“hard and early”? The panel felt that the results of
ongoing prospective studies such as DELIVER-MS [8]
or TREAT-MS [9] (not expected until 2023) should
be awaited before considering general recommenda-
tion of unselected early aggressive treatment.
Instead, the DGN guideline aims at a “treat to target”
approach that requires the definition of DMD categories
based on efficacy, the definition of probably highly active
MS in DMD naive patients, and the definition of inflam-
matory active MS in patients on DMD for more than 6
months based on close monitoring throughout the dis-
ease course. As such, the guideline assists decisions on
which of the growing number of different DMDs can be
offered to the individual patient, including clear guid-
ance on when and how to use higher-efficacy drugs from
the outset in DMD naive individuals considered to suffer
from probably highly active MS.
Key question 3. When should disease-modifying
treatment be stopped?
Generally after a defined time (e.g. 5 years), or later and
sometimes not at all? What about reactivation/rebound
of disease activation?
Discontinuation of DMD treatment is an important issue
that is often addressed in daily practice, in particular by
RMS patients who have remained stable for many years
Fig. 1 Consensus was reached that category 1 drugs should be used as first-line treatment in DMD-naive patients unless the disease course is considered
probably highly active (see A25). Efficacy category 2 and 3 DMDs should be used if category 1 drugs have failed to control the disease. However, apart from
this well-known escalation approach, category 2 and 3 agents should also be offered to DMD-naive patients whose disease course is considered probably
highly active from the beginning (see A29). The choice of category 1 to 3 thus follows both a step-in and a step-up approach. (OLU, off-label use)
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both clinically and radiologically while exposed to long-
term immunotherapy. Whether it is possible to safely stop
treatment in such patients is currently an unresolved
question – as it is for patients with inactive secondary
progressive MS (SPMS).
Hopefully, three ongoing prospective randomised
trials, two including patients with RRMS (DISCOMS
[10], estimated completion date February 2022; DOT-
MS [11], estimated completion date January 2024) and
one including an SPMS population older than 50 years
(Stop-I-SEP [12], estimated completion date January
2026), will clarify the impact of treatment discontinu-
ation on focal disease activity and disability progression
in the foreseeable future. To date, several observational
studies have concluded that discontinuation from
(mostly) injectable DMD does not, in general, impact
freedom from relapses but may have negative effects on
the progression of disability. Age, gender and disability
at baseline or acquired within 3 years before withdrawal
from treatment (with mostly injectable drugs) determine
the risk of not remaining stable in the long term [13–16].
These data are in accordance with circumstantial evidence
that the inflammatory component of MS, and conse-
quently the efficacy of DMD, declines with increasing
age [17, 18].
Taking into account both the available evidence on
withdrawal from treatment and data from observational
studies implying a mild long-term disease course [4, 5]
in some patients, the DGN guideline panel took the
opportunity to draw up recommendations on “treatment
duration and discontinuation” (see A60) in highly selected
patient groups:
In RMS patients with an anticipated mild disease
course at onset (based on clinical and radiological features,
i.e. severity of and recovery from first relapse, relapse fre-
quency, MRI lesion load and activity, and CSF parameters
[see A16]), and stable disease during the preceding 5 years
on category 1 DMD treatment (no further clinical or
radiological MS activity or progression), the guideline (a)
gives a weak recommendation to pause category 1 DMD
treatment; (b) strongly emphasises that patients should be
informed that the advocated period of 5 years is not
evidence-based and that no data from controlled trials
assessing the impact of treatment discontinuation on
future relapses and disability progression are available; (c)
highlights that the decision on whether to pause or not to
pause DMD treatment has to be taken on a strictly indi-
vidual basis and in consideration of the individual patient’s
wishes; and (d) demands regular clinical and MRI assess-
ments to monitor upcoming disease activity (at 6 and 12
months and subsequently every 12months following
discontinuation of treatment (see A65)).
This recommendation only seemingly contradicts the
ECTRIMS/EAN guidelines which recommend “to consider
continuing a DMD if a patient is stable (clinically and on
MRI) and shows no safety or tolerability issues” [3]. Rather,
the ECTRIMS/EAN guidelines pass over the question of
whether there is ever an alternative to permanent DMD
treatment. In contrast, the DGN guideline cautiously
broaches the option of DMD discontinuation in a distinct
patient population fulfilling the criteria described above.
Interestingly, the DGN guideline revives a former
suggestion: The 2006 recommendations on “Escalating
Immunomodulatory Therapy of Multiple Sclerosis”,
authored by the MSTKG panel, included a similarly weak
recommendation that “treatment discontinuation might
be considered after at least 3 years of stable disease (no re-
lapses, no disability progression, stable MRI) by taking
into consideration the patient’s wish and the prerequisite
of patient education and close monitoring” [19].
Regarding category 2 and 3 DMDs, breakthrough or
rebound MS activity after cessation of natalizumab, S1P
modulators and - problably - CD20 antibodies is, of
course, an issue. Thus, the DGN guideline states that
complete cessation of these drugs (without substitution)
can by no means be recommended, even if patients have
been free of any disease activity for 5 years (see A63).
More data are needed to fill the knowledge gap on how
to proceed in this clinical situation.
Key question 4. How strongly do regulatory
aspects have to be reflected in a
recommendation?
Is it appropriate to have equivalent recommendations for
rituximab (off-label) and ocrelizumab and for approved B-
cell-depleting therapies (on-label)?
When assessing the efficacy, safety and tolerability of
therapeutic agents or measures for a specific disease or
treatment situation, medical guidelines are primarily
based on the available evidence in its totality. This evi-
dence can come from different sources: in addition to
pivotal phase II and III studies, it may also include data
from retrospective case series, registries, cohort studies,
and “real world” data. In this respect, it is virtually
inevitable that recommendations in medical guidelines
are not always congruent with the currently approved
indications of various drugs. There may even be no
alternative to recommending such off-label use (OLU) if
no approved drugs are available for a certain medical
need. In this respect, the following constellations of
possible or obvious off-label uses can be distinguished in
guidelines:
 In the absence of alternatives, the guideline
recommends OLU of a drug in situations that are
serious in terms of the patient’s health.
 The guideline recommends a specific active
substance for a particular therapeutic situation, but
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not all manufacturers’ preparations are explicitly
approved for the indication.
 The guideline discusses therapeutic procedures or
medications that are in frequent use although there
is scant evidence in favour of doing so. In the
absence of explicit advice against this practice, the
guideline may be interpreted as sanctioning it.
 The guideline recommends a specific therapeutic
principle and makes no distinction regarding the
approval status of substances that show no
difference in key aspects of the mechanism of action.
The lawfulness and feasibility of OLU differ substan-
tially across the EU. German physicians are allowed to
initiate OLU, because medical practitioners, as a so-
called liberal profession, have the right of free choice of
therapy. However, very strict rules apply to OLU in re-
spect of liability issues, patient education and informed
consent. In addition, the costs are not per se covered by
health insurance - but the insurance funds are by all
means empowered to grant reimbursement on a case-to-
case basis and upon request.
The DGN guideline recommends OLU in several
circumstances:
First, the guideline recommends OLU of drugs if no
labelled medications are available. This is often neces-
sary for the treatment of symptoms, e.g. tremor, ataxia,
nystagmus or bladder dysfunction, and even standard
when it comes to the first-line immunotherapy of neuro-
myelitis optica spectrum diseases and MOG-antibody-
associated diseases.
Second, the guideline advocates the use of drugs that,
in the form of branded products from different manufac-
turers, may be on-label or off-label for a given indication
(e.g. gabapentin for spasticity). Similarly, the guideline
mentions drugs that have at least partially proven effi-
cacy, but for which the German Federal Joint Committee
(G-BA) has decided that they are excluded from reim-
bursement by the statutory health insurance funds (e.g.
phosphodiesterase-5 inhibitors for erectile dysfunction).
Third, the guideline panel decided to group the anti-
CD20 antibodies ocrelizumab and rituximab into a sub-
stance class, even though rituximab is not approved for
the treatment of MS. The main reason for this decision
was that the development and clinical evaluation of
ocrelizumab are clearly based on the early findings of
the phase II studies with rituximab. The two therapeutic
antibodies are also nearly identical in terms of their key
pharmacological properties, and large cohort studies
have demonstrated the long-term efficacy of rituximab
in MS treatment [20–22]. Moreover, until ocrelizumab
was approved and launched, in specialised centres it was
common practice to treat MS patients with rituximab.
The guideline group deemed it essential to ensure that
the treatment of these patients, as long as they are
stable, remains in line with prevailing guidelines – above
all because any change in treatment might expose the
patient to unjustified risk. Of course, when using rituxi-
mab off-label, liability issues and the special reimburse-
ment conditions typical of OLU must be considered.
However, as such, initiation and continuation of treatment
with rituximab is not medical malpractice [23] and consti-
tutes an option in MS.
Appendix
DGN guideline recommendations referred to in the
manuscript
Recommendation A14 (consensus; agreement of > 75–
95% of the panellists): The goals of immunotherapy should
be to prevent or reduce clinical disease activity (relapses
and disease progression) and to maintain quality of life. A
further goal should be the reduction of subclinical disease
activity measurable by magnetic resonance imaging. Realis-
tic treatment goals should be agreed upon with the patient
before starting treatment.
Recommendation A16 (consensus): Immunotherapy
should be started in patients with CIS or MS. If a mild
course can be assumed from the initial presentation
and/or the time course, delaying immunotherapy can be
considered under close monitoring of the course and
after discussion with the patient. The severity of the first
episode, the recovery from it, the number of relapses
during the course, MRI parameters (lesion load, activity)
and CSF parameters should be included in the decision.
Statement A17 (consensus): based on their relative re-
duction in inflammatory activity (relapse rate, MRI activ-
ity, relapse-related progression), immunotherapeutics
can be differentiated into three efficacy categories.
Recommendation A18 (strong consensus; agreement
of > 95% of the panellists): According to their effects on
reduction of relapse rate, immunotherapeutics should be
classified into three categories:
 Efficacy category 1 (relative reduction in relapse rate
compared with placebo of 30–50%): beta-interferons
including peg-interferon, dimethyl fumarate
(combined analysis of pivotal trials), glatirameroids,
teriflunomide
 Efficacy category 2 (relative reduction in relapse rate
compared with placebo of 50–60%): cladribine,
fingolimod, ozanimod
 Efficacy category 3 (relapse rate reduction of > 60%
compared with placebo or > 40% compared with
category 1 agents: alemtuzumab, CD20 antibodies
(ocrelizumab, rituximab), natalizumab.
Recommendation A20 (consensus): In the case of a
first relapse event in which the DIS and DIT criteria are
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not met, and therefore the diagnosis of CIS or RRMS
cannot be made (e.g. isolated optic neuritis, isolated
myelitis), immunotherapy should be given only in excep-
tional cases.
Recommendation A23 (consensus): Immunotherapy
of RRMS should be based on disease activity (taking into
account relapse frequency, relapse severity, response to
relapse therapy, disease progression and MRI findings).
Recommendation A24 (consensus): Untreated pa-
tients with RRMS should be offered immunotherapy if
 at least one clinically objectifiable relapse or
 MRI activity
was detectable in the previous 2 years.
Recommendation A25 (consensus): Because of the
lower long-term safety risks, particularly for beta-
interferons and glatirameroids, efficacy category 1 agents
should generally be used at baseline unless the disease
course is considered to be probably highly active.
Statement A28 (consensus): In treatment-naive pa-
tients, MS should be considered probably highly active if
one or more of the following clinical characteristics are
present:
 A relapse has resulted in a severe deficit relevant to
daily living after the completion of relapse therapy
 Recovery from the first two relapses is poor
 Relapse frequency is high: ≥ 3 in the first 2 years
or ≥ 2 in the 1st year after disease onset
 EDSS ≥3.0 in the first year
 Pyramidal tract involvement in the 1st year of the
disease
Recommendation A29 (consensus): Initiation of
immunotherapy with agents of efficacy category 2 (fingo-
limod, cladribine, ozanimod) or 3 (natalizumab, CD20
antibody) should be offered to treatment-naive patients
if a probably highly active course is present.
Statement A32 (strong consensus): The course of
RMS should be classified as active inflammatory if, in
treated patients, at any time later than 6 months follow-
ing the initiation of immunotherapy
 at least one clinically objectifiable relapse, or
 one clinical relapse and one or more new MS-type
lesions on MRI, or
 on two or more occasions, one or more new MS-type
lesions on MRI
have occurred in a period of up to 2 years.
Recommendation A33 (consensus): Patients who
have an active inflammatory course while receiving
treatment with substances in efficacy category 1 should be
switched to a substance in efficacy category 2 or 3, de-
pending on the extent of disease activity. As with sub-
stances in efficacy category 1, patient-specific aspects
(including side effects, type of application, monitoring,
duration of action, comorbidities) should be taken into ac-
count when choosing a drug from efficacy categories 2
and 3. A switch within category 1 agents or to higher-dose
beta interferons should only be considered if patient-
specific factors argue against a switch to category 2/3.
Recommendation A60 (strong consensus): In patients
who had low disease activity before initiation of im-
munotherapy and have not shown disease activity under
previous therapy with an efficacy category 1 drug, cessa-
tion of treatment may be considered after a period of at
least 5 years at the patient’s request. Patients should be
informed that the period of 5 years is not based on evi-
dence and there have been no controlled discontinuation
studies to reliably assess the risk of re-exacerbation of
disease after discontinuation.
Statement A63 (strong consensus): Currently, no gen-
eral recommendation can be made to “de-escalate” treat-
ment with natalizumab (in continued JCV-AK-negative
patients), S1P modulators, or CD20 antibodies, even if
patients on treatment have shown no disease activity for,
say, 5 years.
Recommendation A65 (consensus): If the patient and
physician decide to “de-escalate” or pause treatment
after weighing all risks, clinical and MRI follow-up
should be performed six and 12months later and at 12-
month intervals thereafter. If disease activity is detected
(see definition of active inflammatory RMS), resumption




All authors have made substantial contributions to the conception of the
work, the interpretation of available evidence and have drafted and revised
the manuscript. All authors have approved the submitted version and have
agreed both to be personally accountable for the author’s own contributions
and to ensure that questions related to the accuracy or integrity of any part
of the work, even ones in which the author was not personally involved, are
appropriately investigated, resolved, and the resolution documented in the
literature.
Funding
The preparation of the position statement was not funded.
Availability of data and materials
n.a. (there is no primary research data included).
Declarations
Ethics approval and consent to participate
n.a. (no human participants, human data or human tissue involved).
Consent for publication
n.a. (no individual person’s data in any form included).
Bayas et al. Neurological Research and Practice            (2021) 3:45 Page 6 of 7
Competing interests
All authors are members of the panel responsible for the current revision
and publication of the DGN S2k-Guideline on diagnosis and treatment of
multiple sclerosis, neuromyelitis optica spectrum diseases and MOG-IgG-
associated disorders. Regarding individual financial conflicts of interest,
please refer to the “Leitlinienreport” to the respective S2k-Guideline (see
www.dgn.org/leitlinien)
Author details
1Universitätsklinikum Augsburg, Klinik für Neurologie und klinische
Neurophysiologie, Augsburg, Germany. 2Technische Universität München,
Fakultät für Medizin, Klinikum rechts der Isar, Klinik für Neurologie, Munich,
Germany. 3Klinik und Poliklinik für Neurologie, Medizinische Fakultät,
Universitätsklinik Köln, Cologne, Germany. 4Neurologische Klinik,
Universitätsklinikum Heidelberg, Heidelberg, Germany.
Received: 23 June 2021 Accepted: 24 June 2021
References
1. Hemmer B, et al. Diagnose und Therapie der Multiplen Sklerose,
Neuromyelitis-optica-Spektrum-Erkrankungen und MOG-IgG-assoziierten
Erkrankungen, S2k-Leitlinie, 2021. Leitlinien für Diagnostik und Therapie in der
Neurologie. 2021; www.dgn.org/leitlinien. Zuletzt abgerufen am 20.06.2021.
Retrieved June 20, 2021.
2. Sorensen, P. S., Sellebjerg, F., Hartung, H. P., Montalban, X., Comi, G., &
Tintore, M. (2020). The apparently milder course of multiple sclerosis:
Changes in the diagnostic criteria, therapy and natural history. Brain, 143(9),
2637–2652. https://doi.org/10.1093/brain/awaa145.
3. Montalban, X., Gold, R., Thompson, A. J., et al. (2018). ECTRIMS/EAN
Guideline on the pharmacological treatment of people with multiple
sclerosis. Multiple Sclerosis Journal, 24(2), 96–120 [Erratum in: Mult Scler,
2020. 26(4):517] und Eur J Neurol, 2018. 25(2):215–37 [Erratum in: Eur J
Neurol, 2018. 25(3):605].
4. Reynders, T., D'Haeseleer, M., De Keyser, J., Nagels, G., & D'Hooghe, M.
B. (2017). Definition, prevalence and predictive factors of benign
multiple sclerosis. eNeurologicalSci, 7, 37–43. https://doi.org/10.1016/j.
ensci.2017.05.002.
5. Chung, K. K., Altmann, D., Barkhof, F., Miszkiel, K., Brex, P. A., O'Riordan, J., …
Chard, D. T. (2020). A 30-year clinical and magnetic resonance imaging
observational study of multiple sclerosis and clinically isolated syndromes.
Annals of Neurology, 87(1), 63–74. https://doi.org/10.1002/ana.25637.
6. Gasperi, C., Salmen, A., Antony, G., Bayas, A., Heesen, C., Kümpfel, T., … for
the German Competence Network of Multiple Sclerosis (2019). Association
of intrathecal immunoglobulin G synthesis with disability worsening in
multiple sclerosis. JAMA Neurology, 76(7), 841–849. https://doi.org/10.1001/ja
maneurol.2019.0905.
7. Iacobaeus, E., Arrambide, G., Amato, M. P., Derfuss, T., Vukusic, S., Hemmer, B.
, … Waubant, E. (2020). Aggressive multiple sclerosis (1): Towards a
definition of the phenotype. Multiple Sclerosis Journal, 26(9), 1031–1044.
https://doi.org/10.1177/1352458520925369.
8. DELIVER-MS: Determining the effectiveness of early intensive versus
escalation approaches for RRMS (NCT03535298).
9. TREAT-MS: Traditional versus early aggressive therapy for multiple sclerosis
trial (NCT03500328).
10. DISCOMS: Discontinuation of disease modifying therapies (DMTs) in
multiple sclerosis (MS) (NCT03073603).
11. DOT-MS: Discontinuing disease-modifying therapies in stable relapsing -
onset multiple sclerosis (NCT04260711).
12. STOP-I-SEP: Disease modifying therapies withdrawal in inactive secondary
progressive multiple sclerosis patients older than 50 years (NCT03653273).
13. Kister, I., Spelman, T., Alroughani, R., et al. (2019). Discontinuing disease-
modifying therapy in MS after prolonged relapse-free period: A propensity
score matched study. Journal of Neurology, Neurosurgery & Psychiatry, 90, e2.
14. Kister, I., Spelman, T., Patti, F., Duquette, P., Trojano, M., Izquierdo, G., …
Butzkueven, H. (2018). Predictors of relapse and disability progression in MS
patients who discontinue disease-modifying therapy. Journal of the
neurological sciences, 391, 72–76. https://doi.org/10.1016/j.jns.2018.06.001.
15. Yano, H., Gonzalez, C., Healy, B. C., Glanz, B. I., Weiner, H. L., & Chitnis, T.
(2019). Discontinuation of disease-modifying therapy for patients with
relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
Multiple sclerosis and related disorders, 35, 119–127. https://doi.org/10.1016/j.
msard.2019.07.021.
16. Kaminsky, A. L., Omorou, A. Y., Soudant, M., Pittion-Vouyovitch, S., Michaud,
M., Anxionnat, R., … Mathey, G. (2020). Discontinuation of disease-
modifying treatments for multiple sclerosis in patients aged over 50 with
disease inactivity. Journal of Neurology, 267(12), 3518–3527. https://doi.org/1
0.1007/s00415-020-10029-9.
17. Weideman, A. M., Tapia-Maltos, M. A., Johnson, K., Greenwood, M., &
Bielekova, B. (2017). Meta-analysis of the age-dependent efficacy of multiple
sclerosis treatments. Frontiers in neurology, 8, 577. https://doi.org/10.3389/
fneur.2017.00577.
18. Dahlke, F., Arnold, D. L., Aarden, P., Ganjgahi, H., Häring, D. A., Čuklina, J.,
Nichols, T. E., Gardiner, S., Bermel, R., Wiendl, H. (2021). Characterization of
MS phenotypes across the age span using a novel data set integrating 34
clinical trials (NO.MS cohort): age is a key contributor to presentation.
Multiple Sclerosis Journal, 28, 1352458520988637. https://doi.org/10.1177/13
52458520988637. Epub ahead of print.
19. Rieckmann, P. (2006). Multiple Sklerose Therapie Konsensus Gruppe (MSTK
G). Escalating immunomodulatory therapy of multiple sclerosis. Update
(September 2006). Nervenarzt, 77, 1506–1513.
20. Alping, P., Frisell, T., Novakova, L., Islam-Jakobsson, P., Salzer, J., Björck,
A., … Piehl, F. (2016). Rituximab versus fingolimod after natalizumab in
multiple sclerosis patients. Annals of neurology, 79(6), 950–958. https://
doi.org/10.1002/ana.24651.
21. Salzer, J., Svenningsson, R., Alping, P., Novakova, L., Björck, A., Fink, K., …
Svenningsson, A. (2016). Rituximab in multiple sclerosis: A retrospective
observational study on safety and efficacy. Neurology, 87(20), 2074–2081.
https://doi.org/10.1212/WNL.0000000000003331.
22. Granqvist, M., Boremalm, M., Poorghobad, A., Svenningsson, A., Salzer, J.,
Frisell, T., & Piehl, F. (2018). Comparative effectiveness of rituximab and other
initial treatment choices for multiple sclerosis. JAMA Neurology, 75(3), 320–
327. https://doi.org/10.1001/jamaneurol.2017.4011.
23. Walter, U., Berthele, A., & Strobl, D. (2020). Anforderungen an etablierten Off-
label-Use in der GKV bei Markteintritt zugelassener Analogpräparate –
beispielhaft dargestellt zur Indikation Multiple Sklerose. KrV Kranken- und
Pflegeversicherung, 72(5), 192–198.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Bayas et al. Neurological Research and Practice            (2021) 3:45 Page 7 of 7
